Pediatric Cancer clinical trials

Explore recruiting pediatric cancer clinical trials.

Recruiting pediatric cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pediatric Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A clinical phase IV trial to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Spain, Italy, France, Netherlands, Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, multinational, pharmacokinetic, safety, and efficacy study with IV NEPA (fosnetupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients undergoing highly emetogenic chemotherapy (HEC). A 2-part study with Phase 2, open-label, randomized, single-dose IV NEPA vs fosaprepitant/ondansetron in single-day HEC and repeated-dose IV NEPA in multi-day HEC (Part I, single cycle) and with Phase 3, double-blind, randomized, repeated-dose IV NEPA vs aprepitant/ondansetron in multi-day HEC (Part II, repeated cycles).

Poland, Greece, Romania

Phase II and Phase III (Integrated) EU CTIS Study details

Pediatric Cancer trials by city

Pediatric Cancer in Toronto Pediatric Cancer in Vancouver Pediatric Cancer in Montreal Pediatric Cancer in Calgary Pediatric Cancer in Edmonton Pediatric Cancer in Ottawa Pediatric Cancer in Winnipeg Pediatric Cancer in Quebec City Pediatric Cancer in Hamilton Pediatric Cancer in Kitchener Pediatric Cancer in London Pediatric Cancer in Halifax Pediatric Cancer in New York Pediatric Cancer in Los Angeles Pediatric Cancer in Chicago Pediatric Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease